Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study

/by

This cohort study aims to assess the outcomes of fibromyalgia patients enrolled in the UK Medical Cannabis Registry prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). A cohort study of fibromyalgia patients treated with oils (Adven®, Curaleaf International, UK), dried flower (Adven®, Curaleaf International, UK) or both CBMPs was performed. Primary outcomes were changes from baseline at 1, 3, 6 and 12 months in validated patient-reported outcome measures.

Read more

Is a Low Dosage of Medical Cannabis Effective for Treating Pain Related to Fibromyalgia? A Pilot Study and Systematic Review

/by

Fibromyalgia is a multifaceted and frequently misunderstood chronic pain disease marked by widespread musculoskeletal pain and cognitive/somatic dysfunction. This trial aims to contribute to the existing knowledge on treating fibromyalgia (FM) with medical cannabis (Cannabis sativa L.) and explore a safer and more effective cannabis administration method. The goal is to provide evidence-based findings that can guide alternative treatment options for FM patients by assessing a pilot study.

Read more

Self-Reported Effects of Medical Cannabis on Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series

/by

To observe the effect of cannabis on fibromyalgia illness severity and related symptoms of depression and anxiety. A retrospective chart review was conducted to identify all patients who indicated fibromyalgia as a primary reason for seeking medical cannabis and completed at least 1 follow-up visit at Harvest Medicine clinics from January 2017 to July 2021. Data extracted from patient charts included Patient Health Questionnaire-9 (PHQ-9) scores, Generalized Anxiety Disorder-7 (GAD-7) scores, and self-reported illness severity scores. Changes in these scores between a patient’s intake and first follow-up visits were calculated and analyzed for significance overall and in different demographic subgroups. Patients for whom no follow-up data were available were excluded.

Read more

Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry

/by

There are limited therapeutic options for individuals with fibromyalgia. The aim of this study is to analyze changes in health-related quality of life and incidence of adverse events of those prescribed cannabis-based medicinal products (CBMPs) for fibromyalgia.  Patients treated with CBMPs for a minimum of 1 month were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in validated patient-reported outcome measures (PROMs). A p-value of <.050 was deemed statistically significant.

Read more

A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?

/by

Analysis of over 100 Cannabis samples quantified for terpene and cannabinoid content and genotyped for over 100,000 single nucleotide polymorphisms indicated that Sativa- and Indica-labelled samples were genetically indistinct on a genome-wide scale. Instead, we found that Cannabis labelling was associated with variation in a small number of terpenes whose concentrations are controlled by genetic variation at tandem arrays of terpene synthase genes.

Read more

Cannabidiol Use, Substitution for Medications, and Perceptions of Effectiveness in Women with Chronic Pelvic Pain

/by

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.
To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

Many cannabinoids display promising non-hallucinogenic bioactivities that are determined by the variable nature of the side chain and prenyl group defined by the enzymes involved in their synthesis.

Read more

Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

/by

Authors Carolina Chaves, MD, Paulo Cesar T Bittencourt, MD, MSc, Andreia Pelegrini, PhD Published in Pain Medicine October 2020 Abstract Objective To determine the benefit of a tetrahydrocannabinol (THC)-rich cannabis…

Read more

Fibromyalgia and the endocannabinoid system

/by

Authors: John M. McPartland Published in Science Direct November 2009 Introduction Fibromyalgia has been characterized as an ‘endocanna- binoid (eCB) deficiency syndrome’, along with other refractory maladies such as irritable…

Read more

Cannabis and Cannabidiol (CBD) for the Treatment of Fibromyalgia

/by

Authors: Amnon A.Berger MD, PhD, Joseph Keefe BM, Ariel Winnick MA, Elasaf Gilbert BS, Jonathan P.Eskander MD, MBA, Cyrus Yazdi MD, Alan D.Kaye MD, PhD, Omar Viswanath MD, Ivan Urits…

Read more

Medical Cannabis for the Treatment of Fibromyalgia

/by

Author: George Habib, Suheil Artul Published in Journal of Clinical Rheumatology August 2018 Abstract Background Background: Fibromyalgia is a chronic pain syndrome, characterized by chronic musculoskeletal pain, fatigue, and mood disturbances….

Read more

Medical Cannabis for the Treatment of Fibromyalgia

/by

Authors: George Habib, Suheil Artul Published in Journal of Clinical Rheumatology August 2018 Abstract Background Fibromyalgia is a chronic pain syndrome, characterized by chronic musculoskeletal pain, fatigue, and mood disturbances. There…

Read more

Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study.

/by

Authors: Valeria Giorgi, Sara Bongiovanni, Fabiola Atzeni, Daniela Marotto, et al
Clinical and experimental rheumatology, January-February 2020
—
OBJECTIVES: To assess any clinical improvement attributable to the addition of medical cannabis treatment (MCT) to the stable (>3 months) standard analgesic treatment of fibromyalgia (FM) patients, the retention rate and any changes in the concomitant analgesic treatment over …

Read more